Medical Professionals Reference (MPR)Needle-Free Emergency Epinephrine Now Available for Pediatric Patients

The FDA-cleared Neffy® 1mg nasal spray offers a needle-free epinephrine option for pediatric patients aged 4 and older weighing 15–30 kg. This innovation enhances emergency allergy care accessibility and safety, especially in non-clinical settings. The product’s availability aligns with seasonal increases in allergen exposure and travel-related risks.

⚕️ Key Clinical Considerations ⚕️

• Indication: Neffy 1mg is approved for emergency treatment of type 1 allergic reactions, including anaphylaxis, in children aged ≥4 years and weighing 15–30 kg.
• Administration: Delivered as a single-dose nasal spray into one nostril; a second dose may be given after 5 minutes if symptoms persist.
• Storage & Shelf Life: Stable at room temperature with tolerance for brief exposure to temperatures up to 122°F; 24-month shelf life.
• Adverse Effects: Common side effects include nasal discomfort, congestion, sneezing, and fatigue—generally mild and self-limiting.
• Access & Affordability: Copay savings and patient assistance programs reduce cost to $25 for eligible patients; retail price is $199 for two devices.

🎯 Clinical Practice Impact 🎯

• Patient Communication: Educate families on proper use, storage, and the importance of carrying two devices at all times.
• Practice Integration: Update anaphylaxis action plans to include Neffy as an alternative to auto-injectors for eligible pediatric patients.
• Risk Management: Reduces accidental injection injuries, a known risk with traditional epinephrine auto-injectors.
• Action Items: Prescribe Neffy for appropriate patients, especially those with needle aversion or access challenges.
• Resource Implications: May improve adherence and emergency preparedness in schools, camps, and travel settings.

More on Anaphylaxis